VTGN VTGN

VistaGen Therapeutics Stock Price

1.60
0.00 (0.0%)
1.60
Volume 0
Bid Price 0.79
Ask Price 1.67
News -
Day High

Low
1.42

52 Week Range

High
3.55

Day Low
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 1.60 04:00:00
Open Price Low Price High Price Close Price Prev Close
1.60
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.60 USD

Period:

Draw Mode:

VistaGen Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 319.52M 199.70M 199.22M $ 1.09M $ - -0.49 -3.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 0.20%

more financials information »

VistaGen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.611.7051.421.571,316,319-0.01-0.62%
1 Month1.992.111.421.761,158,514-0.39-19.6%
3 Months2.442.621.421.951,305,306-0.84-34.43%
6 Months2.883.261.422.341,154,317-1.28-44.44%
1 Year2.543.551.422.482,102,339-0.94-37.01%
3 Years1.603.550.101.781,344,5560.000.0%
5 Years3.283.550.101.731,010,630-1.68-51.22%

VistaGen Therapeutics Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.


Your Recent History
NASDAQ
VTGN
VistaGen T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.